Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes

Nanotechnology. 2013 Oct 11;24(40):405101. doi: 10.1088/0957-4484/24/40/405101. Epub 2013 Sep 12.

Abstract

The targeted therapeutic effect of nano drug delivery system for glioblastoma has been hampered by the weak enhanced permeability and retention (EPR) effect of glioblastoma and the low delivering efficiency of NDDS in glioblastoma tissue. In this study, a tumor-penetrating peptide (RGERPPR), the specific ligand of neuropilin-1 overexpressed on glioblastoma and endothelial cells, was used as a targeting moiety to enhance the anti-glioblastoma effect of doxorubicin liposomes. Firstly, RGERPPR-PEG-DSPE was synthesized and used to prepare the RGERPPR peptide-functionalized liposomes (RGE-LS), which showed vesicle sizes of around 90 nm and narrow size distributions. The cellular uptake and in vivo near-infrared fluorescence imaging test displayed that RGE-LS exhibited increased uptake by glioblastoma cells and intracranial glioblastoma tissues. The cytotoxicity assay and anti-glioblastoma study proved that RGERPPR functionalization significantly enhanced the in vitro inhibitory effect of doxorubicin liposomes on glioblastoma cells and prolonged the median survival time of nude mice bearing intracranial glioblastoma. Finally, the immunofluorescence analysis evidenced that RGE-LS were able to penetrate through tumor vessels and stroma and deep into the whole tumor tissue. The results indicated that tumor-penetrating peptide functionalization is an effective strategy for enhancing the anti-glioblastoma effect of doxorubicin liposomes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / mortality
  • Cell Survival / drug effects
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacokinetics
  • Doxorubicin / pharmacology
  • Doxorubicin / therapeutic use
  • Drug Delivery Systems / methods
  • Glioblastoma / drug therapy*
  • Glioblastoma / mortality
  • Kaplan-Meier Estimate
  • Liposomes / chemistry
  • Liposomes / pharmacokinetics
  • Liposomes / pharmacology*
  • Liposomes / therapeutic use
  • Mice
  • Mice, Nude
  • Peptides / chemistry
  • Peptides / pharmacokinetics
  • Peptides / pharmacology*
  • Peptides / therapeutic use

Substances

  • Antineoplastic Agents
  • Liposomes
  • Peptides
  • Doxorubicin